Next Article in Journal
The Role of DNA Methylation in Common Skeletal Disorders
Previous Article in Journal
Methods, Challenges and Potentials of Single Cell RNA-seq
Previous Article in Special Issue
Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity
Article Menu

Export Article

Open AccessReview
Biology 2012, 1(3), 668-697; doi:10.3390/biology1030668

Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors

Department of Infectious Diseases, The Scripps Research Institute, Scripps Florida, 130 Scripps Way, Jupiter, FL 33458, USA
Author to whom correspondence should be addressed.
Received: 11 October 2012 / Revised: 6 November 2012 / Accepted: 7 November 2012 / Published: 19 November 2012
(This article belongs to the Special Issue Structural and Molecular Biology of HIV)
View Full-Text   |   Download PDF [408 KB, uploaded 19 November 2012]   |  


After entry into the target cell, the human immunodeficiency virus type I (HIV) integrates into the host genome and becomes a proviral eukaryotic transcriptional unit. Transcriptional regulation of provirus gene expression is critical for HIV replication. Basal transcription from the integrated HIV promoter is very low in the absence of the HIV transactivator of transcription (Tat) protein and is solely dependent on cellular transcription factors. The 5' terminal region (+1 to +59) of all HIV mRNAs forms an identical stem-bulge-loop structure called the Transactivation Responsive (TAR) element. Once Tat is made, it binds to TAR and drastically activates transcription from the HIV LTR promoter. Mutations in either the Tat protein or TAR sequence usually affect HIV replication, indicating a strong requirement for their conservation. The necessity of the Tat-mediated transactivation cascade for robust HIV replication renders Tat one of the most desirable targets for transcriptional therapy against HIV replication. Screening based on inhibition of the Tat-TAR interaction has identified a number of potential compounds, but none of them are currently used as therapeutics, partly because these agents are not easily delivered for an efficient therapy, emphasizing the need for small molecule compounds. Here we will give an overview of the different strategies used to inhibit HIV transcription and review the current repertoire of small molecular weight compounds that target HIV transcription. View Full-Text
Keywords: Tat; TAR; inhibitors; small molecule compounds; transcription; latency; chronic cells; HIV-1; HIV-2 Tat; TAR; inhibitors; small molecule compounds; transcription; latency; chronic cells; HIV-1; HIV-2

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mousseau, G.; Valente, S. Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors. Biology 2012, 1, 668-697.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biology EISSN 2079-7737 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top